Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals has announced that director Tiffany Olson has ceased to be a director of the company as of 3 February 2026. At the time of her departure, Olson held 106,550 fully paid ordinary shares in Telix and 52,070 share appreciation rights with a notional exercise price of A$4.95 expiring in May 2026; no additional indirect holdings or contractual interests were disclosed, indicating a straightforward change in board composition that may be of interest to investors monitoring governance and insider holdings.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$20.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing and commercialising diagnostic and therapeutic radiopharmaceuticals, particularly in oncology. Its products and pipeline target cancer imaging and treatment, positioning the company within the growing nuclear medicine and precision oncology market.
Average Trading Volume: 2,064,855
Technical Sentiment Signal: Sell
Current Market Cap: A$3.57B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.